Hi-Tech Pharmacal Co. (NASDAQ:HITK)

Using Peter Lynch motivated stock screen found this gem. Good growth in revenue and EPS. PE less than half the EPS growth rate. Still small enough to grow substantially at <$500M mkt cap.
The single negative is the high institutional ownership (>60%) which brings the analysts following as well.

excellent mgt. and financals

Baby boomer generation will be retiring, these kind of pharmecuticals will skyrocket

Very good annual growth for net income,revenue, net margin and a low PE ratio. An aging population and this company has lots of generics and otc medications.

Low debt. Quick ratio of 5.10 compared to peers of 1.10.

Earnings will be announced. If they outperform as they have during the past several quarters, expect a good bump in price. I expect them to continue to grow over the next several years.

Parabolic rises and the Macronomics are going to be short lived and as previous performance post earnings, this has drifted down. thx.

ready for a breakout always beats earnings recently.

HUGe line of new generics in the next few years.

Debt/equity of zero, Price/earnings of 7.63, market cap of 262.90 million, Return on Invested Capital (TTM) of 23.97, based in New York, United States, focus on generic and OTC drugs.

And with my first pick...

Low PE, tons of cash, tiny debt. But that is not why this is going to be a giant killer. The real reason I see this stock outperforming the market is that they largely operate in the generic prescription market.

Over the next few years several factors will fuel fast growth in this market. First, a vast majority of the drug patents on very big drugs will be expiring over the next couple years. This will mean that the total market share enjoyed by the generic drug makers will go way up. I also think when these patents actually start to expire, the markets will gravitate strongly toward the generic makers.

With the cash to invest in expanding the array of drugs they offer as patents allow it, I can see the market reacting very favorably to this stock over the next two years.

With rising cost of health care and prescription drugs, generic drug manufacturers stand to gain the most. Also has drugs in its pipeline to fight the rapidly growing Diabetes epidemic. Solid company with little debt.

300M market cap, 25% insider ownership, generic drugs, 1 analyst tracking the stock who underestimated EPS by 34% last quarter. Hard to find a fundamental flaw to HITK's story. FYE is 4/30, numbers should confirm rev growth.

I've been looking for an up and coming generic drug co. with great fundamentals and good growth prospects and think I found it. Management appears to have a good head on their shoulders and a solid vision for how to best grow the business. I would wait on a pullback (<23.50) to put real money, but this company has a solid record and a good trajectory to make a good long-term investment.
.

Generic drugs. Future.

Company is in a favorable industry (generic drugs) for the period the country is in, massive health care overhaul. System has to find ways to get less expensive. Just BLEW out earnings and I expect that earnings estimates are still too low going forward.

new generic flonase will revitalize company

A Value Proposition

This volatile generic drug maker is near a 4 year low, yet has over 25% of share price in cash and no debt. As our population ages, they will need more of Hi-Tech's medicines. A lack of proper healthcare will also create even more diabetics who will need to purchase their products.